Lumasiran Sodium is a small interfering RNA (siRNA) therapeutic used for the treatment of primary hyperoxaluria type 1, a rare genetic disorder characterized by the overproduction of oxalate. By inhibiting… Read more
Lumasiran Sodium is a small interfering RNA (siRNA) therapeutic used for the treatment of primary hyperoxaluria type 1, a rare genetic disorder characterized by the overproduction of oxalate. By inhibiting the expression of the gene encoding the hydroxyacid oxidase 1 enzyme, this medication effectively reduces oxalate levels. Laboratories rely on high-quality reference standards of Lumasiran Sodium, including its active pharmaceutical ingredient, to ensure accurate analytical testing and rigorous quality control. This category encompasses a comprehensive selection of related materials, such as pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope-labelled compounds. These research materials are essential for conducting precise impurity profiling, supporting method validation, and ensuring the reliability of purity assessments throughout the drug development and manufacturing lifecycle. Chemists use these specialized reagents to maintain stringent analytical standards and facilitate compliance with regulatory requirements for oligonucleotide-based therapeutics.